Korean Regulatory Overhaul To Cut Drug RnD, Approval Time
This article was originally published in SRA
The South Korean government has unveiled a series of regulatory reforms that are designed to step up the competitiveness of the pharma industry and supply drugs in time for public health emergencies.
You may also be interested in...
2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.